leisure time -WSS

leisure time

author：entertainment 2025-09-30 16:29:42 - browse：1

Adam's take main illustration — Molly Ferguson/STAT

Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban
Next article： Ukrainian soldiers say they owe lives to US

focus

WSS

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

ADA: All diabetes patients should be screened for liver condition

New guidelines on severe brain injury complicate already difficult decisions

New guidelines on severe brain injury complicate already difficult decisions

The strange history of BMI, the body mass index

Brazil's Jair Bolsonaro is barred from running for office until 2030

focus

leisure time

knowledge

Hepatitis C has a cure — but many Americans still lack access to it

Do masks work? RCTs can't tell us

DIEP, the 'gold standard' of breast reconstruction, is under threat

Brazil's Jair Bolsonaro is barred from running for office until 2030

The high cost of giving birth even with insurance

Colonoscopy at 40? Study finds a possible benefit

Hepatitis C has a cure — but many Americans still lack access to it

STAT's guide to the next generation of CAR

Moonlake's readout produced a cash windfall. Risks remain

The sun may be out, but guns are not. A lawsuit challenges a new gun ban on Hawaii beaches

explore

Death of patient in Alzheimer’s trial raises question of possible risks

Gene therapy has helped boys walk. Can scientists keep it that way?

Death of patient in Alzheimer’s trial raises question of possible risks

CDC concerned about possible undetected monkeypox spread in U.K.

Death of patient in Alzheimer’s trial raises question of possible risks

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

focus

hotspot

hotspot

leisure time